![Gustavo Viani summarising the RAPIDO trial](https://oncodaily.com/pub/uploads/2023/08/Gustavo--1280x720.jpeg)
Photo of Gustavo Viani from onconews.com.br
Aug 20, 2024, 14:45
Gustavo Viani summarising the RAPIDO trial
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, University of Sao Paulo, recently posted on X:
“ 2 CTH cycles less do not compromise the results with an increase CR-R:RAPIDO trial!
Methods:
- high-risk locally advanced rectal cancer (LARC).
- Study design: Prospective observational cohort study.
- Treatment: Short-course leading to 4 CAPOX or 6 FOLFOX leading to mesorectal excision or watch-and-wait (W and W) for clinical complete response (cCR).
- Complete response (CR), locoregional recurrences, neurotoxicity.
Outcomes:
- CR rate: RAPIDO trial (24%).
- LRR: decreased (around 5-6%).
- Neurotoxicity: less than RAPIDO trial.”
Source: Gustavo Viani/X
Authors: Bengt Glimelius, Tanweer Khan, Karin Adolfsson, Eva Angenete, Åke Berglund, Kristina Bonde, Nils Elander, Tone Fokstuen, Johan Haux, Israa Imam, Cecilia Lagerbäck, Ingrid Ljuslinder, Andrzej Piwowar, Marie Zajicova, and Per J. Nilsson.
Åke Berglund
Andrzej Piwowar
Bengt Glimelius
cancer
CAPOX
Cecilia Lagerbäck
clinical complete response
Eva Angenete
FOLFOX
Gustavo Viani
Ingrid Ljuslinder
Israa Imam
Johan Haux
Karin Adolfsson
Kristina Bonde
LARC
locally advanced rectal cancer
Marie Zajicova
Nils Elander
OncoDaily
Oncology
Per J. Nilsson
RAPIDO trial
Tanweer Khan
Tone Fokstuen